Objective: Vein graft adaptation is characterized by loss of expression of the tyrosine kinase receptor Eph-B4, the embryonic determinant of venous identity, without increased expression of its ligand ephrin-B2, the embryonic determinant of arterial identity. Endothelial nitric oxide synthase (eNOS) is an important mediator of vessel remodeling. We hypothesized that the mechanism of action of Eph-B4 during vein graft adaptation might be through regulation of downstream eNOS activity. Methods: Mouse lung endothelial cells were stimulated with ephrin-B2/Fc, without and with preclustering, without and with the eNOS inhibitor N u -nitro-L-arginine methyl ester hydrochloride or the Eph-B4 inhibitor NVP-BHG712, and assessed by Western blot and immunofluorescence for eNOS and Eph-B4 phosphorylation. Nitric oxide (NO) production was assessed using an NO-specific chemiluminescence analyzer. Cell migration was assessed using a Transwell assay. Human and mouse vein graft specimens were examined for eNOS activity by Western blot, and vessel remodeling was assessed in vein grafts in wild-type or eNOS knockout mice. Results: Ephrin-B2/Fc stimulated both Eph-B4 and eNOS phosphorylation in a bimodal temporal distribution (n [ 4; P < .05), with preclustered ephrin-B2/Fc causing prolonged peak Eph-B4 and eNOS phosphorylation as well as altered subcellular localization (n [ 4; P < .05). Ephrin-B2/Fc increased NO release (n [ 3; P < .01) as well as increased endothelial cell migration (n [ 6; P < .05) in an eNOS-dependent fashion. Both human and mouse vein grafts showed increased eNOS phosphorylation compared with normal veins (n [ 3; P < .05). Vein grafts from eNOS knockout mice showed less dilation and less wall thickening compared with wild-type vein grafts (n [ 7; P < .05). Conclusions: eNOS is a mediator of vein graft adaptation to the arterial environment. Eph-B4 stimulates eNOS phosphorylation in vitro and may mediate vein graft adaptation by regulation of eNOS activity in vivo. (J Vasc Surg 2017;65:179-89.) Clinical Relevance: To date, despite a large number of clinical trials, no strategy appears effective in improving long-term vein graft patency. Eph-B4 activity regulates vein graft adaptation, and this study shows that Eph-B4 stimulates endothelial nitric oxide synthase (eNOS) phosphorylation, suggesting that Eph-B4 activity during vein graft adaptation is mediated by eNOS. Modulation of eNOS activity may provide a potential new therapeutic target to improve vein graft patency.
Autologous saphenous vein grafts are the preferred conduit for revascularization of advanced peripheral arterial disease. 1, 2 Vein grafts placed in the arterial circulation are subjected to higher arterial pressure and shear stress and remodel to this environment by wall thickening and lumen dilation that normalizes shear stress on the endothelium. 3 In addition to this adaptive response to the change in the hemodynamic environment, vein grafts also respond to the injury of the procedure and the new environment with an inflammatory response. 4 In some patients, the early adaptive remodeling and inflammatory responses become excessive and lead to neointimal hyperplasia with subsequent late vein graft failure. 5 Understanding the mechanisms of how venous adaptive remodeling is finely regulated to balance adaptation without excessive thickening may improve long-term vein graft patency. 4 The tyrosine kinase receptor Eph-B4 and its cognate ligand ephrin-B2 determine the molecular distinction between veins and arteries, respectively, in the early embryo. 6 Despite the reciprocal distribution of venous Eph-B4 and arterial ephrin-B2 during early vascular development, the function of Eph-B4 and ephrin-B2 in normal adult vessels is not well understood. Eph-B4 has been previously thought to be a passive marker of venous identity in adult veins; however, we have previously shown that Eph-B4 is functional during vein graft adaptation by inhibiting vein wall thickening, suggesting that Eph-B4 is functional in adult veins. 7, 8 Stimulation of Eph-B4 inhibits neointimal hyperplasia in adult human veins, further suggesting the potential utility of this pathway for therapeutic modulation. 9 However, the mechanisms by which Eph-B4 regulates vein graft adaptation are not well understood.
Nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS) regulates both physiologic and pathologic vascular functions. 10 Impairment of eNOS-derived NO leads to less vasorelaxation and accelerated smooth muscle cell proliferation and migration that contribute to pathologic neointimal hyperplasia. 11, 12 Despite data that eNOS plays a critical role in arterial remodeling, 12 little is known about its function in venous adaptive remodeling. Therefore, we hypothesized that eNOS may be a downstream mediator of Eph-B4 signaling during venous adaptive remodeling such as occurs during vein graft adaptation to the arterial environment. #SML0333) , and N u -nitro-L-arginine methyl ester hydrochloride (L-NAME; Sigma-Aldrich, catalog #N5751).
METHODS
Cell culture. Mouse lung endothelial cells (MLEC) were isolated from C57Bl/6 or eNOS knockout (KO) mice as previously described 13 ; primary endothelial cells were immortalized by infection with retrovirus encoding the middle T antigen and were maintained with endothelial basal medium-2/endothelial cell growth media-2 MV SingleQuots Kit Supplement & Growth Factors (Lonza, Allendale, NJ), supplemented with 20% fetal bovine serum (FBS; Gibco by Life Technology, Grand Island, NY), penicillin/streptomycin (Corning Life Science, Tewksbury, Mass; 5 mL in total 500 mL of medium), and L-glutamine (Corning Life Science, 5 mL in total 500 mL of medium). Culture medium was changed every 2 days. When cells reached w90% confluence, cells were passaged and split with the use of 0.25% trypsin (Gibco by Life Technology). Where indicated, cells were preincubated with NVP-BHG712 (1 mM) for 1 hour before ephrin-B2/Fc stimulation.
Ephrin-B2/Fc and clustering treatments in vitro. Confluent MLEC were cultured with serum-free endothelial basal medium-2 (Lonza) for 24 hours and then treated with ephrin-B2/Fc (2 mg/mL) for the indicated time. Ephrin-B2/Fc multimers were generated by preincubation of ephrin-B2/Fc with anti-Fc at a ratio of 1:5 (10 mg/mL of anti-Fc with 2 mg/mL of ephrin-B2/Fc dimer) for 30 minutes at room temperature.
NO release analysis. Wild-type (WT) and eNOS KO MLEC were placed in serum-free medium for 24 hours after they reached w90% confluence and pretreated with control or L-NAME (1 mM, 30 minutes) before stimulation with ephrin-B2/Fc (2 mg/mL, 60 minutes). Conditioned medium was then collected and processed with an NO-specific chemiluminescence analyzer as previously described.
14 Cell migration assay. Endothelial cell migration was measured using 8-mm Transwell inserts (Corning Life Science) as previously described. 15 Briefly, WT and eNOS KO cells were starved for 15 hours and placed in a 0.1% gelatin (Sigma-Aldrich)-coated Transwell upper chamber. Cells were pretreated with L-NAME (1 mM, 30 minutes) as indicated. Serum-free medium, ephrin-B2/Fc (2 mg/ mL), or 10% FBS was placed in the lower chamber; FBS was used as a positive control. After 8 hours, cells were fixed, stained, and counted in five representative highpower fields.
Western blot. Cells were lysed in buffer containing radioimmunoprecipitation assay lysis buffer, 10% sodium dodecyl sulfate buffer, protease inhibitor (Roche Diagnostics, Indianapolis, Ind), and phosphatase inhibitor I and II (Calbiochem Merck Millipore, Billerica, Mass). After sonication for 5 seconds and centrifugation at 13,500 rpm for 15 minutes, equal amounts of protein from each group were loaded into a 10% sodium dodecyl sulfatepolyacrylamide gel and then transferred to a polyvinylidene difluoride membrane (Millipore). The membrane was incubated with appropriate primary and secondary antibodies as described before. Membrane signals were detected using the ECL detection reagent (PerkinElmer, Waltham, Mass) and film processor SRX-101A (Konica Minolta, Ramsey, NJ).
Immunoprecipitation. After scraping cells with lysis buffer, the protein concentration was measured using the protein assay reagent (Bio-Rad, Hercules, Calif) and normalized to 1.25 mg/mL. Samples were incubated with phosphotyrosine mouse monoclonal antibody (Sepharose bead conjugate) overnight at 4 C. Samples were processed for analysis by Western blot.
Immunofluorescence. Cells were grown on a square 18-Â 18-mm sterile microscope cover glass (Fisherbrand, Thermo Fisher Scientific, Waltham, Mass) placed in the well of a six-well plate that was coated with 0.1% gelatin (Sigma-Aldrich). After stimulation, cells were fixed with acetone (J.T.Baker) at À20 C for 15 minutes and then permeabilized in 0.1% phosphate-buffered saline with 0.1% Triton X-100 for 15 minutes. Cells were blocked with 10% goat serum (Vector Laboratories, Burlingame, Calif) for 1 hour, then incubated with primary antibody diluted in blocking buffer overnight in 4 C. Secondary detection was performed using Alexa Fluor 488 and 568 for 2 hours and counterstained with DAPI.
Vein graft tissue processed for immunofluorescence was fixed with formalin and embedded in paraffin, cut into 5-mm sections, and placed on slides. Tissue sections were deparaffinized using xylene and a graded series of alcohols. Antigen retrieval was conducted by boiling with 10 mM citric acid (pH 6) for 30 minutes. Slides were blocked with 1% bovine serum albumin before incubation with primary antibody overnight in 4 C. Alexa Fluor 488 and 568 were used for fluorescence.
Human specimens. The principles outlined in the Declaration of Helsinki were followed, and approval of the institutional Human Investigation Committee was obtained. Deidentified patent saphenous vein grafts were explanted from human patients undergoing cardiac transplantation or from patients with a patent peripheral bypass undergoing amputation for distal ischemia without infection, as previously described. 7 Lysis buffer was added to samples to extract protein and processed for Western blot.
Mouse vein graft model. All protocols were approved by Yale University's Institutional Animal Care and Use Committee and were performed and administered within National Institutes of Health and ethical guidelines. The mouse vein graft model was performed as previously described. 8 Briefly, 12-week-old C57BL/6 WT and eNOS KO mice (Jackson Laboratory) were purchased. An approximately 2.0-mm segment of the intrathoracic inferior vena cava (WT or eNOS KO) was isolated and implanted into the infrarenal abdominal aorta of a recipient WT mouse. The abdominal aorta was temporarily occluded with atraumatic microclamps, and a segment corresponding to the length of the vein graft was excised. The vein was sutured into the arterial circulation using 10-0 nylon in continuous fashion. Vein grafts were observed postoperatively using the Vevo 770 High-Resolution Imaging System (VisualSonics, Toronto, Ontario, Canada). At 3 weeks after surgery, mice were sacrificed and vein grafts were fixed by transcardial perfusion of phosphate-buffered saline, followed by 10% formalin. Vein grafts were removed and fixed overnight in 10% formalin, followed by 70% alcohol for 24 hours. Tissue was embedded in paraffin and sectioned (5 mm thick). Tissue sections were deparaffinized and either stained with hematoxylin and eosin or processed for immunofluorescence.
Statistics. Western blot results were quantitated with ImageJ software. Data are expressed as mean 6 standard error of the mean. The statistical significance was determined using the t-test or analysis of variance with appropriate post hoc testing between groups. Differences were considered to be significant at P < .05 (Prism 6.0; GraphPad, La Jolla, Calif).
RESULTS
Because both Eph-B4 and eNOS regulate vessel remodeling, 8, 12 we determined if stimulation of Eph-B4 activates eNOS in MLEC in vitro. We previously showed that MLEC express both Eph-B4 and ephrin-B2, consistent with a venous phenotype. 16 As expected, stimulation of endothelial cells with ephrin-B2/Fc stimulated Eph-B4 phosphorylation, in a bimodal temporal distribution, with an early peak at approximately 1 minute and a later peak at approximately 30 to 60 minutes (Fig 1, A) . In addition to ephrin-B2/Fc stimulating Eph-B4 phosphorylation, ephrin-B2/Fc also stimulated eNOS phosphorylation, in a similar bimodal pattern (Fig 1, B) , that was inhibited in cells pretreated with the Eph-B4 inhibitor NVP-BHG712 (Fig 1, C) . Because Eph receptor signaling is triggered by clustered ligands 17 and multimeric forms may have increased magnitude or temporal pattern of receptor activation, 18 we examined the effect of clustered ephrin-B2/ Fc on Eph-B4 phosphorylation. Multimeric ephrin-B2/ Fc was generated by clustering ephrin-B2/Fc with antiFc antibodies, 18 using an ephrin-B2/Fc:anti-Fc ratio of 1:5 to maximally enhance Eph-B4 phosphorylation (data not shown). Clustered ephrin-B2/Fc also stimulated Eph-B4 phosphorylation in a bimodal pattern similar to unclustered ephrin-B2/Fc, although the early peak of phosphorylation appeared to be sustained to 5 minutes, potentially consistent with increased Eph-B4 activation with the clustered ligand (Fig 1, D) . Clustered ephrin-B2/Fc also stimulated eNOS phosphorylation, but in a unimodal distribution, of greater maximal magnitude compared with unclustered ephrin-B2/Fc (Fig 1, E) . These results suggest that activation of Eph-B4 with ephrin-B2/Fc stimulates eNOS phosphorylation in vitro (Fig 1, F) , eg, eNOS may be a downstream mediator of Eph-B4 signaling in endothelial cells.
To confirm the interaction between Eph-B4 and eNOS in MLEC in vitro, we used immunofluorescence to determine if Eph-B4 and peNOS colocalized in endothelial cells after ephrin-B2/Fc stimulation. Before stimulation, Eph-B4 immunoreactivity was primarily detected in the endothelial cell nucleus; after ephrin-B2/Fc stimulation, Eph-B4 immunoreactivity was enhanced in the cytoplasm within 5 minutes (Fig 2) . peNOS immunoreactivity was enriched in the perinuclear region and also found diffusely in the cytoplasm, and maximal enhancement of peNOS immunoreactivity was seen 15 minutes after ephrin-B2/Fc stimulation (Fig 2) . Colocalization of Eph-B4 with peNOS was observed in the cytoplasm after ephrin-B2/Fc stimulation (Fig 2, arrows) . Stimulation with preclustered ephrin-B2/Fc showed a similar pattern of phosphorylation and colocalization at 5 and 15 minutes compared with ephrin-B2/Fc, but with sustained localization of Eph-B4 in the cytoplasm at 6 hours (Fig 2, arrowheads) . As expected, total eNOS expression was similar in all conditions (data not shown), consistent with similar total eNOS expression detected with Western blot (Fig 1, C and D) . Because colocalization of Eph-B4 and peNOS suggests that Eph-B4 and peNOS may interact with each other in endothelial cells, we performed coimmunoprecipitation of Eph-B4 and peNOS; however, immunoprecipitation using a peNOS-specific antibody was unable to coprecipitate any Eph-B4 protein (data not shown), suggesting only indirect interaction between Eph-B4 and peNOS. In toto, these data suggest that activation of Eph-B4 enhances endothelial cell eNOS phosphorylation in vitro.
To determine whether stimulation of Eph-B4 signaling is linked to a functional eNOS pathway, we determined if eNOS is a mechanism of Eph-B4-mediated NO release and endothelial cell migration. Stimulation of endothelial cell Eph-B4 enhanced NO release into the medium that was inhibited in cells pretreated with L-NAME, both basally and after Eph-B4 stimulation (Fig 3, A) . Similarly, there was less NO release in eNOS KO endothelial cells compared with WT endothelial cells, both basally and after Eph-B4 stimulation (Fig 3, B) . Stimulation of Eph-B4 similarly enhanced endothelial cell migration that was also inhibited with L-NAME (Fig 3, C) ; eNOS KO endothelial cells also had less basal as well as less Eph-B4-stimulated migration (Fig 3, D) . These results suggest that some Eph-B4-mediated endothelial cell functions are mediated by eNOS signaling. phosphorylation (E) after preclustered ephrin-B2/Fc (2 mg/mL; ephrin-B2/Fc:anti-Fc ratio, 1:5) stimulation. D, n ¼ 3; *P ¼ .0496; **P ¼ .0146; ***P ¼ .0032. E, n ¼ 4; *P ¼ .0484. F, Schematic of the Eph-B4-eNOS pathway in vitro. In isolated endothelial cells, treatment of Eph-B4 with ephrin-B2/Fc stimulates Eph-B4 and eNOS phosphorylation; these effects are enhanced (red arrows) in the presence of the clustered multimeric ephrin-B2/Fc. showing mean nitric oxide (NO) release in response to ephrin-B2/Fc (2 mg/mL, 60 minutes), without or with N unitro-L-arginine methyl ester hydrochloride (L-NAME) pretreatment (1 mM, 30 minutes); n ¼ 3; *P ¼ .0018; **P ¼ .0013; ***P < .0001. B, Bar graph showing mean NO release in response to ephrin-B2/Fc (2 mg/mL, 30 minutes) in wild-type (WT) or eNOS knockout (KO) endothelial cells; n ¼ 4; *P ¼ .0076; **P < .0001; ***P < .0001. C, Bar graph showing endothelial cell migration in response to ephrin-B2/Fc (2 mg/mL, 8 hours) or 10% fetal bovine serum (FBS), without or with L-NAME pretreatment (1 mmol, 30 minutes); n ¼ 6; *P ¼ .0376; **P < .0001. D, Bar graph showing endothelial cell migration in response to ephrin-B2/Fc (2 mg/mL, 8 hours) or 10% FBS in WT or eNOS KO endothelial cells; n ¼ 5; *P < .0001; **P ¼ .0217; ***P < .0001; ****P < .0001.
Because vein graft adaptation is associated with reduced Eph-B4 expression, 7 we determined if eNOS is phosphorylated during vein graft adaptation in both human and mouse vein grafts. 8 In patent human vein grafts, eNOS phosphorylation was increased 1.9-fold in vein grafts compared with saphenous veins (Fig 4, A) . Similarly, eNOS phosphorylation was increased 3-fold in vein grafts after 21 days compared with the mouse inferior vena cava (Fig 4, B) . Immunofluorescence confirmed increased expression of peNOS in the endothelial cells of both human and mouse vein grafts compared with veins (Fig 4, C) . Because we have previously reported that Eph-B4 expression was decreased in vein grafts compared with saphenous veins, 7 these results suggest that diminished Eph-B4 expression during vein graft adaptation is associated with increased eNOS phosphorylation in vivo, eg, Eph-B4 is an early upstream regulator of later downstream eNOS activity.
To determine if eNOS is a mechanism that mediates vein graft adaptation, we compared eNOS KO vein grafts with WT vein grafts after implantation into WT host mice. Serial ultrasonography of the vein grafts showed that eNOS KO vein grafts developed thinner walls over time compared with WT vein grafts (Fig 5, A) , consistent with previous data showing increased wall thickness over time in WT vein grafts. 8 Histology similarly showed that eNOS KO vein grafts had thinner walls compared with WT vein grafts at 21 days after implantation (Fig 5, B  and C) . eNOS KO vein grafts also showed smaller vessel area (Fig 5, D) , consistent with less outward remodeling. Although eNOS KO vein grafts showed less wall thickness and less outward remodeling compared with WT vein grafts, there was no significant difference in lumen area (Fig 5, E) . These results are consistent with a mechanistic role for eNOS during vein graft adaptation.
To confirm a mechanistic role for eNOS, because eNOS is downstream from Eph-B4, we hypothesized that eNOS KO vein grafts would have increased expression of Eph-B4. As expected, control vein grafts showed diffuse eNOS immunoreactivity in endothelial cells, whereas eNOS immunoreactivity was not detected in eNOS KO vein grafts (Fig 6, A, first column, and B) . Also as expected, in control vein grafts, Eph-B4 immunoreactivity was barely detectable; however, in eNOS KO vein grafts, Eph-B4 immunoreactivity was comparatively increased (Fig 6, A,  second column, and B) . Furthermore, there was more phosphotyrosine immunoreactivity in eNOS KO vein grafts (Fig 6, A, third column) as well as increased colocalization of phosphotyrosine with Eph-B4 in eNOS KO vein grafts compared with control vein grafts (Fig 6, A, last column,  and B) . These data suggest that reduced vessel remodeling lumen area in WT and eNOS KO mice. C, n ¼ 7; *P ¼ .0462. D, n ¼ 7; *P ¼ .028. E, n ¼ 7; P ¼ .3273. and wall thickness in eNOS KO vein grafts (Fig 5) is associated with increased or persistent expression of upstream Eph-B4. These results are consistent with feedback regulation of Eph-B4 (Fig 6, C) , suggesting that the Eph-B4 and eNOS pathways may be functionally linked during vein graft adaptation.
DISCUSSION
We show that ephrin-B2/Fc stimulates Eph-B4 and eNOS phosphorylation in endothelial cells in a timedependent manner in vitro (Fig 1) , with colocalization of Eph-B4 and eNOS in the endothelial cell cytoplasm (Fig 2) . Compared with the ephrin-B2/Fc dimer, the multimeric form of ephrin-B2/Fc shows sustained activation of Eph-B4 and eNOS. Eph-B4 activation promotes NO release and endothelial cell migration, and this stimulation is eliminated in the absence of eNOS (Fig 3) . eNOS phosphorylation is increased in both human and mouse vein grafts in vivo (Fig 4) . Lack of eNOS expression prevents adaptive thickening and remodeling of the venous wall (Fig 5) and increases Eph-B4 expression (Fig 6) , suggesting that eNOS negatively feeds back on Eph-B4 expression during vein graft adaptation. In toto, these results suggest that eNOS is a downstream mediator of Eph-B4 that regulates venous adaptive remodeling to the arterial environment.
It is established that Eph-B4 is an embryonic determinant of the venous endothelium, whereas its ligand ephrin-B2 is a determinant of arterial fate during development of the vascular system. [19] [20] [21] [22] We have previously shown that Eph-B4 expression is diminished during vein graft adaptation in adults, suggesting that successful vein graft adaptation, characterized by increased venous wall thickness and adaptive outward remodeling, is associated with loss of venous identity. 7, 8 Our data also suggest that Eph-B4 is a negative regulator of eNOS during vein graft adaptation in vivo, with reduced Eph-B4 expression during vein graft adaptation associated with enhanced eNOS phosphorylation after 3 weeks (Fig 4) although not at 1 week postoperatively, 15 consistent with successful vein graft adaptation Eph-B4, and merge of Eph-B4 and p-Tyr; n ¼ 3; *P ¼ .0017; **P ¼ .0011; ***P ¼ .0002. C, Schematic of the Eph-B4-eNOS pathway during vein graft adaptation in vivo. During vein graft adaptation, Eph-B4 expression is decreased, allowing eNOS activity to promote adaptive venous remodeling. eNOS negatively regulates Eph-B4 activity in a feedback loop; when eNOS is not present, venous remodeling is reduced and Eph-B4 activity is enhanced.
at 3 weeks in this model. Improving vein graft adaptation with increased NO production has led to the use of eNOS as a potential therapeutic agent. 11, 23 However, the regulation of successful vein graft adaptation to the arterial circulation, with just the "right amount" of wall thickening and dilation, without progression to neointimal hyperplasia or aneurysmal dilation, is not currently understood. 24 Downstream regulators of Eph-B4 signaling in the endothelial cell include Akt, ERK1/2, 25,26 and caveolin-1. 8 Our finding that eNOS is phosphorylated with stimulation of Eph-B4 in adult venous endothelial cells is consistent with previous reports that have shown that activation of Eph-B4 enhances NO production in endothelial cells in vitro. 8, 25 We previously showed that reduced endothelial Eph-B4 signaling in endothelial cells derived from heterozygous Eph-B4 mice 27 was associated with diminished basal levels of eNOS protein expression and NO production but increased tube formation, 15 consistent with our data in vitro (Fig 3) , but emphasizing the differences of endothelial cell function in vitro and in three dimensions, especially during vein graft adaptation in vivo.
eNOS is regulated by phosphorylation, 28, 29 and Akt phosphorylates eNOS and enhances the ability of eNOS to generate NO. 14 We have previously shown that reduced Eph-B4 function is associated with increased basal Akt phosphorylation in endothelial cells but not in whole vein grafts, 15 suggesting a link from Eph-B4 to eNOS through the Akt pathway, at least in endothelial cells. In addition, caveolin-1 interacts with eNOS and negatively regulates eNOS phosphorylation, 30, 31 and we have previously shown that caveolin-1 is a mediator of vein graft adaptation, 8 eg, the Eph-B4-eNOS pathway is quite complex, 10 and the activity of this pathway during vein graft adaptation is likely to have additional layers of regulation in vivo. Differences between Eph-B4-eNOS pathway activity in vitro, eg, Eph-B4 activation is associated with increased eNOS phosphorylation (Figs 1 and 2 ) and function (Fig 3) , and pathway activity in vivo, eg, diminished Eph-B4 expression is associated with increased eNOS activity (Figs 4 and 5) , are likely to be due to several factors. First, the in vitro data reflect rapid interaction between Eph-B4 and eNOS over minutes, whereas the in vivo data reflect results after weeks. Second, the in vitro data are derived solely from endothelial cells, whereas the in vivo data are derived from whole vessels that have other cell types; of note, Eph-B4 is present predominantly in venous endothelial cells, but it is present to a lesser extent in smooth muscle cells. 8 Third, the in vitro data may reflect differences between MLEC and the in vivo large-vessel endothelial cells; in addition, MLEC are immortalized and may have higher basal expression of Akt and eNOS compared with primary cells. There are likely to be other important differences as well; nonetheless, our in vitro data suggest a link between Eph-B4 and eNOS signaling in endothelial cells that is also present in vein grafts in vivo.
NO is produced by three isoforms of NO synthase: neuronal, inducible, and endothelial. Inducible NO synthase (iNOS) has been previously reported to be involved in vein graft adaptation to the arterial environment. Veins produce less NO compared with arteries, 32 and after vein graft implantation, endothelial injury and denudation are associated with further reduced eNOSderived NO. 33 Early reports of iNOS expression after arterial injury 34 led several groups to show that iNOS delivery to vein grafts can lead to improved nitrite release 35 and less neointimal hyperplasia. 36, 37 However, iNOS may be associated with increased superoxide and peroxynitrite production and thus may not be optimal for human treatment to prevent graft failure 38 despite its positive effects. 39 eNOS is typically thought to be protective for vessels, and reduced eNOS is associated with vein graft neointimal hyperplasia. 40 eNOS is induced in veins exposed to arterial shear stress, 41 and delivery of eNOS to vein grafts inhibits neointimal hyperplasia. 11, 23 Interestingly, the vein graft vasa vasorum may be a source of eNOS promoting vein graft adaptation. 42 We reported that Eph-B4 regulates vein graft adaptation through caveolin-1, 8 and our data suggest that Eph-B4-caveolin-1 signaling may regulate downstream eNOS, a potential target for therapeutic modulation.
Unlike other receptor tyrosine kinases, Eph receptor activation in vitro requires membrane attachment or clustered ligands. 17 Therefore, to activate Eph-B4 receptors, we used the homodimer ephrin-B2/Fc that consists of the extracellular domain of mouse ephrin-B2 fused to the Fc region of human IgG. In addition, different oligomerization states of the ligands can be discriminated by Eph receptors and contribute to downstream cellular responses. 18 Therefore, we also used a preclustered multimeric ephrin-B2/Fc to stimulate Eph-B4 and showed that both dimeric and preclustered multimeric ephrin-B2/Fc stimulated Eph-B4 phosphorylation (Figs 1 and 2) , as expected. 18 However, the multimeric ephrin-B2/Fc showed a longer duration of Eph-B4 phosphorylation and increased eNOS phosphorylation; these results are consistent with activation of Eph-B1 by multimeric ephrin-B1/Fc, 18 eg, the multimeric form of Eph receptor ligands enhances receptor activation and signaling (Fig 1, F) . The bimodal distribution of Eph-B4 and eNOS phosphorylation after ephrin-B2/Fc stimulation (Fig 1, A and B) suggests the presence of downstream fast and slow pathways of receptor activation and signal transduction. Stimulation of Eph-B4 with the preclustered multimeric ephrin-B2/Fc enhanced the activity of the fast pathway (Fig 1, D and E) and allowed sustained detection of Eph-B4 in the endothelial cell (Fig 2) ; however the significance of these two pathways in not yet known.
CONCLUSIONS
Increased eNOS phosphorylation in both human and mouse vein grafts is consistent with an active response to the hemodynamic changes that occur during vein graft adaptation. Because diminished Eph-B4 expression actively regulates vein graft adaptation, 7, 8 our results linking Eph-B4 with eNOS suggest that eNOS phosphorylation is an essential mechanism of Eph-B4 function during venous adaptive remodeling. As such, the Eph-B4-eNOS pathway may be a potential specific target for therapeutic manipulation to enhance vein graft patency.
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